Jon Faiz Kayyem, Director, on September 16, 2026, executed a purchase for 5,000 shares in Inhibrx Biosciences (INBX) for $500,000. Following the Form 4 filing with the SEC, Kayyem has control over a total of 1,069,046 common shares of the company, with 1,069,046 controlled indirectly.
SEC Filing:
John E Kao, Director, Chief Executive Officer, on September 14, 2026, sold 27,400 shares in Alignment Healthcare (ALHC) for $356,200. Following the Form 4 filing with the SEC, Kao has control over a total of 1,814,239 common shares of the company, with 1,223,473 shares held directly and 590,766 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1832466/000162828026062329/xslF345X05/wk-form4_1789595865.xml
Thomas Donald Brisbin, Director, on September 15, 2026, sold 4,905 shares in Willdan Group (WLDN) for $389,254. Following the Form 4 filing with the SEC, Brisbin has control over a total of 96,687 common shares of the company, with 96,687 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1370450/000139518826000010/xslF345X05/form4-09162026_090951.xml
Niraj Shah, Director, Chief Executive Officer, on September 14, 2026, sold 69,000 shares in Wayfair (W) for $7,131,390. Following the Form 4 filing with the SEC, Shah has control over a total of 313,994 Class A common shares of the company, with 291,137 shares held directly and 22,857 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1616707/000161670726000162/xslF345X05/wk-form4_1789593603.xml